Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
54 hedge funds and large institutions have $151M invested in Sienna Biopharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 10 reducing their positions, and 7 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 10
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 53 → 54 (+1)
0% more capital invested
Capital invested by funds: $151M → $151M (+$194K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.43M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.77M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.07M |
| 5 |
BlackRock
New York
|
+$475K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$2.74M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.5M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$785K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$421K |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$372K |
SNNA Hedge Fund Activity: Q3 2018 in Review
54 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q3 2018, worth a combined $151M — up 0.13% from $151M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SNNA positions and 7 closed out — a net gain of 1 holder — while 26 added to existing stakes and 10 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.43M. The largest seller was IFP Advisors, exiting entirely with an estimated $2.74M sold.
- 54 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q3 2018, up from 53 in Q2 2018.
- Funds reported $151M of Sienna Biopharmaceuticals, Inc. stock for Q3 2018, up 0.13% quarter-over-quarter.
- 8 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q3 2018 and 7 closed out, a net change of +1 holder.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q3 2018 was Morgan Stanley, an estimated $2.43M added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q3 2018 was IFP Advisors, an estimated $2.74M sold.
Based on aggregated 13F filings for Q3 2018.